Tandem Diabetes Care Q2 sales rise 6% to $254.6 million; net loss narrows
Tandem Diabetes Care reported second quarter 2026 sales of $254.6 million, up 6% from $240.7 million a year earlier, with gross margin of 57% versus 52%. GAAP net loss narrowed to $21.2 million from $52.4 million, and the company reaffirmed its full-year 2026 sales guidance, which matters to shareholders because it shows revenue growth and lower losses while the company updated only its non-cash expense outlook.
Key points
- Worldwide sales of $254.6 million, including $179.3 million in the U.S., up 5% in the U.S. and 7% internationally
- GAAP net loss of $21.2 million, compared with $52.4 million in the second quarter 2025, which included a $20.0 million litigation settlement expense
- Full-year 2026 sales guidance reaffirmed at approximately $1.065 billion to $1.085 billion
- Non-cash charges guidance lowered to approximately $85 million from $100 million
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.